MEA Mycoplasma Testing Market

MEA Mycoplasma Testing Market Size (2024 to 2029)

The size of the mycoplasma testing market in the Middle East and Africa is predicted to be worth USD 111.37 Million by 2029 and USD 74.99 Million in 2024, growing at a CAGR of 8.23% from 2024 to 2029.

Increasing cases of cell culture contamination across MEA is one of the key factors propelling the growth of the mycoplasma testing market in MEA. Mycoplasma cell culture is invisible but causes severe damage to the species' body. Not detected early may lead to high costs and sometimes mortality. Mycoplasma pneumoniae is the bacteria responsible for damaging the lining of the respiratory system. People suffering from mycoplasma pneumonia have bacteria in their noses or throat. These diseases or illness is spread from an infected person to other people through droplets from the nose and the throat when they cough or sneeze. In adults, these infections are primarily due to being sexually transmitted, causing nongonococcal urethritis, some prostate inflammation in men, and vaginal discharge and pelvic inflammatory disease (PID) in women. As a result, mycoplasma testing is mainly used to determine whether there is a presence of infection or not in the species. Different types of body samples can be used for mycoplasma testing.

The growing number of R&D activities and approval of novel devices for mycoplasma testing fuel regional market growth. Many key players have focused on developing devices with advanced features to increase test accuracy. They also focused on developing rapid tests, which help with fast bacteria testing. Increasing investment by the pharmaceutical and biotechnologies sector, reimbursement policies, and product approval also help the demand for market growth. In addition, advanced methods such as nucleic acid amplification techniques detect unknown contaminates.

The scarcity of more skilled professionals for mycoplasma testing is significantly restraining the market growth. The high cost of the raw material used in cell culture and related materials is another factor that challenges the market growth. Lack of awareness, long term approvals for novel products also challenge market growth.

This research report on the MEA Mycoplasma Testing Market has been segmented and sub-segmented into the following categories:

By Product: 

• Kits & Reagent       
  • PCR Assays
  • Nucleic Acid Detection Kits
  • Elimination Kits & Reagents
  • Stains
  • Standards & Controls
  • Other Kits & Reagents
• Instruments           
• Services    

By Technique: 

• PCR            
• ELSA           
• Direct Assays          
• Indirect Assays      
• Microbial culture techniques           
• Enzymatic Methods            
• DNA Staining       

By Application: 

• Cell Line Testing
• Virus Testing
• End-Of-Production Cell Testing
• Others

By End-User: 

• Pharmaceutical Companies
• Contract Research Organizations
• Academic Research Institutes
• Cell Banks

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Middle East Africa held a moderate share of the worldwide market in 2022. However, the regional market is predicted to grow at a steady growth rate during the forecast period owing to the increasing awareness about mycoplasma testing and increasing infrastructure facilities in the region. In addition, increasing awareness programs about mycoplasma testing among the population favor the market growth in MEA.

Egypt is predicted to account for a considerable share of the MEA market during the forecast period owing to the growing use of mycoplasma testing in the domestic sector. Mycoplasma gallisepticum is the bacteria primarily seen in species. It increases the mortality rate and leads to severe economic loss. In animals, inhalation of egg transmission air and borne droplets are the main reason for the disease's transmission. Mycoplasma gallisepticum has affected nearly 83 percent of turkey in the country. Increasing meat consumption among the population is the main reason for the increasing demand for mycoplasma testing kits.

Saudi Arabia is another noteworthy regional market for mycoplasma testing market in MEA. It is expected to register a healthy CAGR during the forecast period owing to the increasing number of clinical trial centers. The clinical center helps develop and test a new virus in the body and helps manufacture the mycoplasma testing kits. As a result, sponsors are showing interest in increasing their investment in manufacturing the mycoplasma-related kits is propelling the market growth in Saudi Arabia.

UAE is expected to hold a notable share of the MEA market in the coming years owing to increasing mycoplasma infections, the UAE government has taken several measures to detect and prevent the various types of mycoplasma infection among the species. Mycoplasma pneumoniae infections are also seen in school-aged children due to the surrounding environment. It is also seen in people who are present in college residence halls, military training facilities, long-term care facilities, and hospitals.

KEY MARKET PLAYERS:

PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, and WuXi AppTec are a few of the notable companies in the MEA mycoplasma testing market.